Modus Outcomes’ own Stefan Cano co-authored a paper describing  the development of a computerized adaptive test (CAT) to shorten the BREAST-Q’s Satisfaction with Breasts scale while maintaining reliability of measurement. The goal of the research was to decrease response burden and help overcome barriers to implementation in routine clinical care. The BREAST-Q is widely used in clinical practice, surgical research and clinical trials (currently in 84 ongoing trials as a primary or secondary endpoint). The BREAST-Q has also been acknowledged at the US Food and Drug Administration (FDA) for its state of the art development and validation.

If you are interested in learning more about the BREAST-Q CAT or the Q-Portfolio, please visit or contact Andrea Murison to schedule a call or a training session with our experts.